TME Pharma Updates Strategy for NOX-A12 Development

TME Pharma, a clinical-stage biotechnology company based in the Netherlands, has provided an update on its strategic approach and financial discipline as it navigates a pivotal phase in developing its lead asset, NOX-A12. The company, which specializes in therapies for brain cancer and eye diseases, is focused on securing an outcome that reflects the significant potential of NOX-A12.

According to Diede van den Ouden, CEO of TME Pharma, the company’s management philosophy is centered on long-term shareholder alignment. Van den Ouden emphasized that the company is strictly controlling overhead and personal compensation is structured to emphasize long-term performance and share price appreciation. The CEO also highlighted that personal investments and capital contributions have been made to protect existing shareholders from unnecessary dilution.

Since June 2025, TME Pharma has implemented a disciplined cost-reduction strategy that has extended its financial runway into the second quarter of 2027. The company has maintained a limited level of dilution through the use of standard bond financing, ensuring that it retains independence and time to negotiate from a position of strength. This approach has been crucial in securing the financial resources necessary to advance NOX-A12.

Van den Ouden noted that TME Pharma is currently evaluating potential strategic partners to capitalize on the favorable market dynamics in the biotech sector. The company is observing increased capital flows and strategic demand for clinical-stage assets, positioning itself to leverage these conditions for the benefit of its shareholders.

TME Pharma’s lead asset, NOX-A12, is being studied in the GLORIA Phase 1/2 clinical trial for newly-diagnosed brain cancer patients who do not benefit from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma has received Fast Track Designation for NOX-A12 in combination with radiotherapy and bevacizumab for the treatment of glioblastoma. NOX-A12 has also received orphan drug designation for glioblastoma in the United States and glioma in Europe.

In addition to NOX-A12, TME Pharma is also developing NOX-E36, an emapticap pegol, which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effects. The company is exploring opportunities to secure the financial resources to unlock the value of both assets, including raising funds from alternative sources and pursuing stable, cash-generating business opportunities.